Glucagon-like peptide-1 (GLP-1) compounds have emerged as a compelling therapeutic avenue for managing metabolic syndromes. These naturally occurring hormones are secreted by the gut in response to meal intake, stimulating insulin production and suppressing glucagon output. GLP-1 agents demonstrate promising therapeutic results in treating type 2 d